Incyte Corporation · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-12-06$75.92 RISE2025-04-10$55.17 PEAK2025-06-16$71.22 192d | -27.3% 125d | Missed | Missed | — | — | +29.1% 67d | Missed |
DROP2024-01-04$66.59 RISE2024-04-25$51.18 PEAK2024-07-19$65.87 197d | -23.1% 112d | Missed | Missed | — | — | +28.7% 85d | Missed |
DROP2023-08-11$65.93 RISE2023-10-30$52.16 PEAK2024-01-04$66.59 146d | -20.9% 80d | Missed | Missed | — | — | +27.7% 66d | Missed |
DROP2022-07-21$82.86 RISE2022-09-26$66.18 PEAK2022-12-08$84.11 140d | -20.1% 67d | Missed | Missed | — | — | +27.1% 73d | Missed |
DROP2022-04-08$83.18 RISE2022-06-14$66.18 PEAK2022-07-21$82.86 104d | -20.4% 67d | Missed | Missed | — | — | +25.2% 37d | Missed |
DROP2021-07-23$79.30 RISE2021-11-22$63.34 PEAK2022-01-24$75.34 185d | -20.1% 122d | Missed | Missed | — | — | +18.9% 63d | Missed |
DROP2020-07-20$109.69 RISE2020-11-24$80.74 PEAK2021-01-25$100.50 189d | -26.4% 127d | Missed | Missed | — | — | +24.5% 62d | Missed |
DROP2020-01-02$85.97 RISE2020-03-23$63.18 PEAK2020-04-24$103.48 113d | -26.5% 81d | Missed | Missed | — | — | +63.8% 32d | Missed |
DROP2020-01-02$85.97 RISE2020-02-03$72.94 PEAK2020-04-24$103.48 113d | -15.2% 32d | Missed | Missed | — | — | +41.9% 81d | Missed |
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f
Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f
Incyte (INCY) shows explosive 304% EPS growth and strong sales acceleration. With a High Growth Momentum Rating of 6 and a breakout setup rating of 8, it offers a favorable risk/reward entry for momentum investors.
Bernstein analyst Jeffrey Walch initiates coverage on Incyte (NASDAQ:INCY) with a Market Perform rating and announces Price Target of $99.
In May 2026, Incyte and Edison Scientific announced a collaboration to embed Edison’s Kosmos AI platform across Incyte’s discovery and development lifecycle, while Incyte also expanded its partnership with Genesis Molecular AI through a US$120,000,000 investment and at least five new small‑molecule targets under the GEMS platform. Together, these agreements mark a shift toward treating Incyte’s proprietary data as a compounding asset, with AI systems continuously learning to support target...
In May 2026, Incyte and Edison Scientific announced a collaboration to embed Edison’s Kosmos AI platform across Incyte’s discovery and development lifecycle, while Incyte also expanded its partnership with Genesis Molecular AI through a US$120,000,000 investment and at least five new small‑molecule targets under the GEMS platform. Together, these agreements mark a shift toward treating Incyte’s proprietary data as a compounding asset, with AI systems continuously learning to support target...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $135 price target.
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026--Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery
Incyte Corporation (INCY) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:30 AM EDTCompany ParticipantsSteven Stein - Executive VP,...
WILMINGTON, Del. & SAN FRANCISCO, May 19, 2026--Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the
Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the
Incyte Corporation (INCY) Bank of America Global Healthcare Conference 2026 May 13, 2026 4:40 PM EDTCompany ParticipantsWilliam Meury - CEO &...
WILMINGTON, Del., May 12, 2026--Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Incyte Corporation is among the best cancer stocks to invest in. On May 7, INCY reported final 24-week results from its Phase 3 TRuE-AD4 study evaluating Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had limited […]
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Incyte Corporation is among the best cancer stocks to invest in. On May 7, INCY reported final 24-week results from its Phase 3 TRuE-AD4 study evaluating Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had limited […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| INCY | -0.18% | -3.30% | -2.06% | +48.69% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.14% | +2.42% | +1.39% | +36.01% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 9.64M | $907.45M | 0.03% | Unchanged | 2026-03-31 |
| RenTech | quant | 3.65M | $343.68M | 0.54% | Trimmed-8.2% | 2026-03-31 |
| Wellington | fundamental | 3.27M | $307.41M | 0.06% | Added+341.7% | 2026-03-31 |
| FidelityFMR | fundamental | 1.17M | $110.39M | 0.01% | Trimmed-5.9% | 2026-03-31 |
| TwoSigma | quant | 415.9K | $39.15M | 0.03% | Added+1031.8% | 2026-03-31 |
| Citadel | multi-strat | 168.8K | $15.88M | 0.02% | New | 2026-03-31 |
| Bridgewater | macro | 130.3K | $12.26M | 0.05% | Trimmed-60.3% | 2026-03-31 |
| TRowePrice | fundamental | 751.9K | $70.77K | 0.01% | Trimmed-22.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | BIENAIME JEAN JACQUES | Director | M Option exercise(deriv) | 15,000 | — | +$0 |
| 2026-05-28 | BIENAIME JEAN JACQUES | Director | F Tax withholding | 13,059 | $97.10 | −$1.27M |
| 2026-05-28 | BIENAIME JEAN JACQUES | Director | M Option exercise | 15,000 | $84.53 | +$1.27M |
| 2026-05-28 | Tray Thomas | Principal Accounting Officer | S Open-market sale | 2,051 | $97.35 | −$199.7K |
| 2026-05-21 | Clancy Paul J | Director | M Option exercise(deriv) | 15,000 | — | +$0 |
| 2026-05-21 | Clancy Paul J | Director | S Open-market sale | 15,000 | $94.93 | −$1.42M |
| 2026-05-21 | Clancy Paul J | Director | M Option exercise | 15,000 | $84.53 | +$1.27M |
| 2026-05-06 | Upadhyay Suketu | EVP & Chief Financial Officer | A Grant / award(deriv) | 13,171 | — | +$0 |
| 2026-05-06 | Upadhyay Suketu | EVP & Chief Financial Officer | A Grant / award(deriv) | 38,429 | — | +$0 |
| 2026-05-06 | Upadhyay Suketu | EVP & Chief Financial Officer | A Grant / award | 26,343 | — | +$0 |
| 2026-04-21 | CAGNONI PABLO J | President, Global Head of R&D | M Option exercise(deriv) | 12,590 | — | +$0 |
| 2026-04-21 | CAGNONI PABLO J | President, Global Head of R&D | M Option exercise(deriv) | 6,077 | — | +$0 |
| 2026-04-21 | CAGNONI PABLO J | President, Global Head of R&D | S Open-market sale | 18,667 | $96.50 | −$1.80M |
| 2026-04-21 | CAGNONI PABLO J | President, Global Head of R&D | M Option exercise | 12,590 | $71.93 | +$905.6K |
| 2026-04-21 | CAGNONI PABLO J | President, Global Head of R&D | M Option exercise | 6,077 | $64.25 | +$390.4K |
| 2026-04-17 | Stein Steven H | CMO & Head of Late-Stage Dev. | A Grant / award | 39,049 | — | +$0 |
| 2026-04-17 | CAGNONI PABLO J | President, Global Head of R&D | A Grant / award | 27,892 | — | +$0 |
| 2026-04-17 | Meury William | Chief Executive Officer | M Option exercise | 125,000 | — | +$0 |
| 2026-04-02 | Clancy Paul J | Director | A Grant / award | 265 | $94.12 | +$24.9K |
| 2026-04-02 | HARRIGAN EDMUND | Director | A Grant / award | 269 | $94.12 | +$25.3K |
| 2026-03-26 | Trotta Matteo | EVP, GM, Dermatology US | F Tax withholding | 537 | $92.23 | −$49.5K |
| 2026-03-19 | CAGNONI PABLO J | President, R&D | M Option exercise(deriv) | 11,501 | — | +$0 |
| 2026-03-19 | CAGNONI PABLO J | President, R&D | M Option exercise(deriv) | 7,166 | — | +$0 |
| 2026-03-19 | CAGNONI PABLO J | President, R&D | S Open-market sale | 18,667 | $94.24 | −$1.76M |
| 2026-03-19 | CAGNONI PABLO J | President, R&D | M Option exercise | 11,501 | $64.25 | +$738.9K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-28upcoming | 1.82 | — | — |
| 2026-04-28 | 1.34 | 1.81 | +35.12% |
| 2026-02-10 | 1.51 | 1.46 | -3.13% |
| 2025-10-28 | 1.34 | 2.11 | +57.83% |
| 2025-07-29 | 1.47 | 1.57 | +6.59% |
| 2025-04-29 | 1.03 | 1.16 | +12.32% |
| 2025-02-10 | 1.55 | 1.43 | -8.01% |
| 2024-10-29 | 0.79 | 0.54 | -31.26% |
| 2024-07-30 | 1.11 | -1.82 | -264.53% |
| 2024-04-30 | 0.83 | 0.64 | -23.09% |
| 2024-02-13 | 1.15 | 1.06 | -7.71% |
| 2023-10-31 | 1.07 | 1.10 | +3.10% |
| 2023-08-01 | 0.87 | 0.99 | +14.45% |
| 2023-05-02 | 0.74 | 0.37 | -50.02% |
| 2023-02-07 | 0.57 | 0.62 | +8.14% |
| 2022-11-01 | 0.71 | 0.60 | -14.93% |